AstraZeneca shares plunge as the firm's lung cancer study fails
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
The so-called Mystic study was the most anticipated clinical experiment in the pharmaceutical industry this year and the news saw the shares tumble more than 15 per cent in early trade, putting them on track for their worst day ever.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
